***NEOGEN *** Einstiegschance - 500 Beiträge pro Seite

[Kostolanys Erbe]

über neogen wurde schon mal häufiger auf diesem board diskutiert.jetzt bietet sich für langfristige aktionäre eine gute einstiegsgelegenheit.



aktie ist völlig überverkauft.

Kosto

[Kostolanys Erbe]

Neogen Named to The Bloomberg 100

/FROM PR NEWSWIRE DETROIT 248-352-5200/ [STK] NEOG [IN] MTC BIO AGR MAG [SU]

Neogen Named to The Bloomberg 100


LANSING, Mich., Jan. 10 /PRNewswire-FirstCall/ -- Neogen Corporation (Nasdaq: NEOG) has been named to The Bloomberg 100, an annual listing of top performing stocks.

The Bloomberg 100, which appears in the January/February edition of Bloomberg Personal Finance, ranked Neogen 47th on the list with a 144% 1-year total return in 2001. Bloomberg editors noted that companies on the list succeeded in a year when market success stories "were fewer and smaller."

"We`re obviously pleased with the recognition, but we are even more proud of our uninterrupted 10-year record of growth, consistent profits and a strong balance sheet," said Richard Current, Neogen`s chief financial officer. "Exceptional performance is what our investors have come to expect from us, and what we expect from ourselves."

Neogen`s Bloomberg 100 recognition follows the Company`s second consecutive inclusion on Forbes Magazine`s annual list of the 200 Best Small Companies in America, as well as Neogen being named one of only four Michigan companies to be given a perfect "A+" rating in the annual review of public companies by The Detroit News.

In December, Neogen released second quarter results that set all-time Company records for both revenue and earnings. Neogen`s second quarter revenues were $10,699,000 -- the first time the Company`s quarterly revenues had exceeded $10 million. Revenues were 19% greater than the prior year`s second quarter. The quarter marked the 40th time in the previous 44 quarters that the Company reported increases in revenue compared to the prior year. Revenues for the Company`s first six months were $20,431,000 compared to $17,133,000. Earnings per share were $0.18 for the second quarter, ended Nov. 30, 2001, as compared with $0.15. Earnings per share for the first six months were $0.32 per share, as compared to $0.27. On a year-to-date basis, operating profits were 49% greater than the prior year.

Neogen Corporation develops and markets products and services dedicated to food and animal safety. The Company`s Food Safety Division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. Neogen`s Animal Safety Division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals and nutritional supplements.

Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward- looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management`s Discussion and Analysis of Financial Condition and Results of Operations in the Company`s most recently filed Form 10-K.


Neogen Reports Record Quarter

LANSING, Mich., Dec. 19 /PRNewswire/ -- Neogen Corporation (Nasdaq: NEOG) announced today that its second quarter set all-time Company records for both revenue and earnings.

Neogen`s second quarter revenues were $10,699,000 -- the first time the Company`s quarter revenues have exceeded $10 million. Revenues were 19% greater than last year`s second quarter of $9,009,000. This marks the 40th quarter in the last 44 quarters the Company has reported increases in revenue compared to the prior year. Revenues for the Company`s first six months were $20,431,000 compared to $17,133,000 in the prior year.

Earnings per share were $0.18 for the second quarter, ended Nov. 30, 2001, as compared with $0.15 for the same period last year. Earnings per share for the first six months were $0.32 per share, as compared to $0.27 for the prior year. Neogen`s operating profits for the quarter increased 46% compared to a year earlier. On a year-to-date basis, operating profits were 49% greater than last year.

"All of the Company`s operating units within its Food Safety and Animal Safety divisions have shown nice growth in both revenue and profits for our first six months," said James Herbert, Neogen`s president. "This continued strong financial performance led Forbes Magazine again to name Neogen one of the Top 200 Small Companies in America. New distribution agreements signed during the quarter, and the release of new products should enable the Company to maintain its growth strategy for the remainder of the year."

The Animal Safety Division`s growth was led by deliveries of the Company`s new D3(TM) hypodermic needles. Animal producers are using the new needles because of their superior strength, and easy detectability by processing plant metal detectors. The Food Safety Division`s growth was led by a 29% increase in revenues from rapid diagnostic tests used to detect foodborne pathogens and toxins.

"We are particularly pleased with our strong sales across all product lines in October and November, which enabled us to overcome the slower sales we experienced in September," said Lon Bohannon, Neogen`s chief operating officer. "The aftermath of the tragedies of Sept. 11 halted much of our distribution for several days, which resulted in a loss of sales that were not recovered."

During the quarter, Neogen introduced a new rapid diagnostic test kit for the detection of drug residues in animals and two new test kits to detect genetic modification in corn and soybeans. Significant progress was also made by the Company`s research and development teams, which should result in the release of other new diagnostic test kits for both food and animal safety before fiscal year end.

The continued integration of companies acquired in earlier quarters helped increase gross margins to 53% for the quarter, as compared to 50% for the same quarter a year earlier. Continued integration also helped improve operating income to 16% of revenues as compared to 13% a year earlier. During the quarter, Neogen successfully moved all operations of Gene-Trak Systems that it had acquired in August to the Company`s Lansing, Mich., location. The new Gene-Trak DNA probe technology should provide expanded new product opportunities for both food and animal safety diagnostic tests.

Neogen Corporation develops and markets products and services dedicated to food and animal safety. The Company`s Food Safety Division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. Neogen`s Animal Safety Division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals and nutritional supplements.

NEOGEN CORPORATION SUMMARIZED CONSOLIDATED OPERATING DATA
(In thousands, except for per share data)

Quarter ended Nov. 30 Six months ended Nov. 30
2001 2000 2001 2000
Revenue $10,699 $9,009 $20,431 $17,133
Gross Margin 5,673 4,544 10,565 8,540
Operating Income 1,694 1,160 2,929 1,962
Net Income 1,145 860 2,007 1,532
Net Income Per Share $0.18 $0.15 $0.32 $0.27


NEOGEN CORPORATION SUMMARIZED CONSOLIDATED BALANCE SHEET DATA
(In thousands)

Nov. 30 May 31
2001 2001
Assets
Current Assets $20,139 $21,579
Property and Equipment 3,150 2,721
Goodwill 11,432 7,076
Other Assets 1,759 1,646
$36,480 $33,022

Liabilities & Stockholders` Equity
Current Liabilities $3,034 $3,335
Long-term Liabilities 326 350
Equity 33,120 29,337
$36,480 $33,022


Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward- looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management`s Discussion and Analysis of Financial Condition and Results of Operations in the Company`s most recently filed Form 10-K.


nur mal so als info....

Kosto